Profile data is unavailable for this security.
About the company
Genus plc is a United Kingdom-based animal protein genetics company. The Company supplies breeding animals with desirable characteristics for farmers, enabling them to produce quality meat and milk. Its segments include Genus PIC, Genus ABS and Genus Research and Development. The Genus PIC segment is engaged in the porcine sales business. The Genus ABS segment is engaged in the bovine sales business. Its bovine genetics business sells dairy and beef bull semen and embryos from its superior cattle, which are sold to farmers to breed their cows through artificial insemination. Its porcine genetics business sells genetically superior breeding pigs and semen to farmers, so they can breed commercial pigs with desirable characteristics for pork production. It also provides technical services and advice to farmers, to maximize the performance of its breeding animals in their farms. The Company has supply chain and distribution networks in over 80 countries.
- Revenue in GBP (TTM)673.10m
- Net income in GBP33.40m
- Incorporated1994
- Employees3.48k
- LocationGenus PLCMatrix House, Basing ViewBASINGSTOKE RG21 4DZUnited KingdomGBR
- Phone+44 125 634 7100
- Fax+44 125 647 7385
- Websitehttps://www.genusplc.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eckert & Ziegler SE | 217.65m | 29.20m | 822.61m | 1.07k | 27.73 | 4.04 | 19.87 | 3.78 | 1.65 | 1.44 | 12.27 | 11.29 | 0.5834 | 3.08 | 4.72 | 237,931.20 | 7.98 | 8.50 | 9.75 | 10.23 | 48.42 | 48.61 | 13.68 | 14.00 | 2.24 | 21.89 | 0.1919 | 35.09 | 10.74 | 7.84 | -2.84 | 13.22 | 33.82 | -30.12 |
| EIS czcbs lc Sn v Fnnsl Ytrmlr Sny v Tcr | 157.75m | 66.70m | 880.89m | 1.12k | 13.21 | 1.04 | 11.03 | 5.58 | 4.00 | 4.00 | 9.46 | 50.85 | 0.1578 | 3.00 | 4.85 | -- | 6.67 | 8.82 | 7.16 | 9.40 | 33.76 | 32.94 | 42.29 | 58.23 | 1.14 | -- | 0.0813 | -- | 86.94 | 56.41 | -8.16 | 62.73 | 141.59 | 31.51 |
| Calliditas Therapeutics AB | 97.73m | -39.12m | 924.70m | 219.00 | -- | 93.00 | -- | 9.46 | -9.78 | -9.78 | 24.43 | 2.24 | 0.7541 | 3.16 | 8.97 | 6,723,169.00 | -30.19 | -26.46 | -38.05 | -30.27 | 95.01 | -- | -40.03 | -76.59 | 2.62 | -3.99 | 0.8943 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| BioGaia AB | 96.94m | 27.68m | 926.77m | 211.00 | 34.76 | 5.95 | 31.41 | 9.56 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Polypeptide Group AG | 276.32m | -43.75m | 961.91m | 1.20k | -- | 2.95 | -- | 3.48 | -1.52 | -1.52 | 9.59 | 11.31 | 0.5137 | 2.31 | 5.08 | 264,248.20 | -8.13 | 2.59 | -10.37 | 3.26 | 2.81 | 23.73 | -15.83 | 4.58 | 1.12 | -1.56 | 0.2466 | 15.79 | 14.60 | 12.36 | -762.29 | -- | 25.40 | -- |
| AddLife AB | 730.40m | 5.89m | 1.00bn | 2.29k | 176.46 | 2.70 | 13.24 | 1.38 | 0.6483 | 0.6483 | 80.41 | 42.38 | 0.7393 | 3.62 | 5.53 | 4,258,149.00 | 0.6112 | 5.31 | 0.9299 | 8.83 | 37.16 | 36.89 | 0.8267 | 5.79 | 0.4778 | 1.48 | 0.5173 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
| FAES Farma SA | 394.71m | 80.63m | 1.02bn | 1.75k | 12.41 | -- | 10.52 | 2.59 | 0.3066 | 0.3066 | 1.50 | -- | -- | -- | -- | 265,361.00 | -- | 13.07 | -- | 15.20 | 66.19 | 64.10 | 20.36 | 19.79 | -- | -- | -- | -- | 2.83 | 6.83 | 2.63 | 12.24 | 39.26 | 52.23 |
| Vetoquinol SA | 450.38m | 47.28m | 1.03bn | 2.48k | 21.72 | 2.29 | 14.99 | 2.29 | 4.70 | 4.70 | 44.73 | 44.53 | 0.7876 | 2.39 | 5.74 | 213,157.90 | 8.27 | 7.09 | 10.44 | 9.40 | 50.31 | 61.27 | 10.50 | 8.84 | 1.86 | -- | 0.0324 | 16.48 | -1.95 | 7.54 | 15.76 | 8.91 | 5.98 | 12.11 |
| Cosmo Pharmaceuticals NV | 82.27m | 975.63k | 1.08bn | 325.00 | 1,016.72 | 2.72 | 81.39 | 13.13 | 0.0696 | 0.0696 | 5.86 | 25.99 | 0.1473 | 3.06 | 2.88 | 290,988.70 | 0.2051 | 0.2437 | 0.249 | 0.267 | 59.33 | 57.28 | 1.39 | 2.10 | 3.80 | 2.73 | 0.0042 | 841.86 | -5.26 | 8.07 | -93.34 | -- | 9.62 | -- |
| Biotest AG | 665.95m | 150.53m | 1.16bn | 2.43k | 9.26 | 3.10 | -- | 1.74 | 4.47 | 4.47 | 19.78 | 13.34 | 0.5936 | 1.14 | 3.83 | 322,588.60 | 13.42 | -0.0693 | 16.72 | -0.079 | 44.24 | 28.43 | 22.60 | -0.1527 | 0.9139 | 5.34 | 0.5677 | -- | 32.65 | 11.33 | 490.89 | -- | -9.36 | -- |
| Fagron NV | 649.26m | 60.03m | 1.17bn | 3.46k | 19.47 | 2.96 | 12.77 | 1.81 | 0.9664 | 0.9664 | 10.45 | 6.35 | 0.7715 | 3.87 | 12.43 | 220,517.60 | 7.18 | 7.63 | 8.76 | 9.77 | 43.59 | 43.49 | 9.31 | 10.23 | 1.27 | 4.45 | 0.4395 | 16.28 | 11.57 | 10.10 | 1.34 | 10.48 | 19.64 | 20.11 |
| Genus plc | 673.10m | 33.40m | 1.19bn | 3.48k | 35.66 | 2.07 | 15.43 | 1.77 | 0.5053 | 0.5053 | 10.18 | 8.71 | 0.6478 | -- | 6.03 | 193,642.10 | 2.90 | 3.58 | 3.30 | 4.20 | -- | -- | 4.47 | 5.44 | 1.40 | 5.44 | 0.3377 | 60.86 | 16.23 | 7.96 | -18.58 | 26.70 | 9.36 | 4.24 |
| Bonesupport Holding AB | 48.88m | 19.87m | 1.25bn | 121.00 | 62.89 | 29.54 | 60.34 | 25.50 | 4.05 | 4.05 | 9.96 | 8.61 | 1.19 | 0.657 | 6.36 | 6,245,276.00 | 48.22 | -9.08 | 61.41 | -11.28 | 92.01 | 90.25 | 40.65 | -11.65 | 2.42 | -- | 0.0282 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Evotec SE | 660.84m | -77.17m | 1.31bn | 5.06k | -- | 1.39 | -- | 1.98 | -0.5124 | -0.5124 | 4.39 | 6.24 | -- | -- | -- | 153,447.10 | -- | -0.0064 | -- | -0.0076 | 20.16 | 24.51 | -11.68 | -0.0178 | 1.79 | -2.09 | 0.3619 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
| BioArctic AB | 18.80m | -9.11m | 1.33bn | 90.00 | -- | 21.58 | -- | 70.85 | -1.38 | -1.38 | 2.86 | 11.24 | 0.2202 | -- | -- | 2,866,000.00 | -10.66 | 2.24 | -11.67 | 2.56 | 83.38 | 86.52 | -48.44 | 9.76 | -- | -- | 0.0043 | 0.00 | 169.83 | -2.91 | 2,150.71 | -9.69 | 11.83 | -- |
| Galapagos NV | 249.67m | 26.13m | 1.44bn | 646.00 | 55.23 | 0.5859 | -- | 5.78 | 0.466 | 4.23 | 4.45 | 43.93 | 0.0653 | 0.1892 | 6.11 | 454,184.20 | 0.6829 | -1.48 | 0.7594 | -1.65 | 123.06 | -- | 10.47 | -14.42 | 9.70 | -- | 0.0028 | -- | 3.47 | -2.02 | 94.42 | -- | 7.04 | -- |
Data as of May 31 2024. Currency figures normalised to Genus PLC's reporting currency: UK Pound GBX
47.89%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baillie Gifford & Co.as of 01 Sep 2023 | 5.68m | 8.61% |
| Wellington Management Co. LLPas of 01 Sep 2023 | 3.93m | 5.96% |
| Vanguard Advisers, Inc.as of 01 Mar 2024 | 3.65m | 5.53% |
| Capital Research & Management Co. (World Investors)as of 01 Sep 2023 | 3.29m | 4.98% |
| abrdn Investments Ltd.as of 01 Sep 2023 | 2.98m | 4.52% |
| Threadneedle Asset Management Ltd.as of 01 Sep 2023 | 2.82m | 4.28% |
| Devon Equity Management Ltd.as of 01 Sep 2023 | 2.79m | 4.22% |
| BlackRock Fund Advisorsas of 01 Sep 2023 | 2.59m | 3.92% |
| The Vanguard Group, Inc.as of 01 Sep 2023 | 2.31m | 3.50% |
| Norges Bank Investment Managementas of 01 Mar 2024 | 1.58m | 2.39% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
